Real-world use of submaximal doses of long-acting GLP-1 receptor agonist semaglutide in patients with obesity: a prospective observational study

Z Zuzana Miertová P Patrik Lecký B Boris Focko T Tomáš Bolek M Martin Jozef Péč J Jakub Jurica N Norbert Nagy P Peter Galajda M Marián Mokáň M Matej Samoš

Article Details

Volume / Issue Vol. 1, Issue 1
Published June 04, 2026
ISSN 2045-2322
Publisher Nature Portfolio

Journal Info

Scientific Reports

Nature Portfolio

ISSN: 2045-2322 Open Access Life Sciences

Authors (10)

Z

Zuzana Miertová

P

Patrik Lecký

B

Boris Focko

T

Tomáš Bolek

M

Martin Jozef Péč

J

Jakub Jurica

N

Norbert Nagy

P

Peter Galajda

M

Marián Mokáň

M

Matej Samoš